Litcius/Paper detail

Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action

Kanzo Suzuki, Ji‐Woon Kim, E. D. Nosyreva, Ege T. Kavalali, Lisa M. Monteggia

2021Cell Reports51 citationsDOIOpen Access PDF

Abstract

Ketamine is a noncompetitive glutamatergic N-methyl-d-aspartate receptor (NMDAR) antagonist that exerts rapid antidepressant effects. Preclinical studies identify eukaryotic elongation factor 2 kinase (eEF2K) signaling as essential for the rapid antidepressant action of ketamine. Here, we combine genetic, electrophysiological, and pharmacological strategies to investigate the role of eEF2K in synaptic function and find that acute, but not chronic, inhibition of eEF2K activity induces rapid synaptic scaling in the hippocampus. Retinoic acid (RA) signaling also elicits a similar form of rapid synaptic scaling in the hippocampus, which we observe is independent of eEF2K functioni. The RA signaling pathway is not required for ketamine-mediated antidepressant action; however, direct activation of the retinoic acid receptor α (RARα) evokes rapid antidepressant action resembling ketamine. Our findings show that ketamine and RARα activation independently elicit a similar form of multiplicative synaptic scaling that is causal for rapid antidepressant action.

Topics & Concepts

AntidepressantNeuroscienceNMDA receptorPharmacologyHippocampusAMPA receptorSignal transductionGlutamatergicBiologyGlutamate receptorChemistryReceptorCell biologyBiochemistryNeuroscience and Neuropharmacology ResearchTryptophan and brain disordersTreatment of Major Depression
Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action | Litcius